| |
 |
|
Chaperone
Tecnologies, Inc. is developing antimicrobial
products, based on a novel and proprietary mechanism of action,
for difficult-to-treat and drug-resistant organisms across a
broad range of infectious diseases.
Chaperone’s proven technology has already yielded the
company’s first product, a potent antimicrobial which
is in development for treating complicated drug resistant
Urinary Tract Infections.
Our core technology platform can produce a sustainable pipeline
of unique products for human and non-human applications, including:
Antimicrobials, antifungals, and antiparasitics targeting
multi-drug resistant organisms across a range of infectious
diseases
A family of biopesticides, feed additives, biopreservatives,
antifungals, and insecticides
A family of non-toxic antimicrobials and biocides for the
meat, poultry and aquaculture processing industries
Novel Mechanism of Action
Chaperone’s research is centered around our discoveries
of the proven activity of native, short, proline-rich peptides
and their derivatives, and the use of our novel pyrrhocoricin
and drosocin-based analogs, to block protein folding by inhibiting
interaction with the molecular chaperone DnaK.
DnaK is a unique, vital, intracellular structure that is responsible
for correcting misshapen proteins, a necessary step in the
life of any organism. When Chaperone’s compounds bind
to intracellular DnaK, it is prevented from performing its
critical role in the organism’s cellular lifecycle,
therefore killing the target organism.
As the binding site of our proprietary peptides is distinct
from homologous targets in mammals, this suggests that these
peptides are non-toxic to humans---and offer a novel and potent
mechanism of action to which infectious diseases have not
developed resistance.
Lead Compound
Chaperone's lead compound, CHP-105, is being developed for
the treatment of complicated urinary tract infections. It
exhibits high potency vs. multi-drug resistant variants of
major uropathogens in vitro under conditions where standard
antibiotics remain inactive, and significantly reduces bacterial
counts in animal UTI models.
Chaperone believes that an IND is possible within 12-18 months.
Chaperone will expand development of its proprietary target-specific
technology into products for treating a broad array of susceptible
organisms.
Based on their activity profile and unique mechanism, Chaperone’s
compounds are expected to potentially exhibit efficacy across
an even broader array of multi-drug resistant organisms and
fungi, such as those responsible for Respiratory Tract Infections
(especially those causing life-threatening lung infections
in cystic fibrosis patients), gastrointestinal infections,
and fungal/parasitic diseases.
|
